Provided by Tiger Trade Technology Pte. Ltd.

Cellectar Biosciences

3.04
+0.22007.80%
Post-market: 3.040.00000.00%18:56 EST
Volume:46.13K
Turnover:138.76K
Market Cap:12.89M
PE:-0.29
High:3.13
Open:2.85
Low:2.85
Close:2.82
52wk High:20.59
52wk Low:2.45
Shares:4.24M
Float Shares:4.06M
Volume Ratio:1.35
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.6249
EPS(LYR):-41.8902
ROE:-145.42%
ROA:-72.31%
PB:1.72
PE(LYR):-0.07

Loading ...

Cellectar BioSciences Showcases Pipeline Advancements and Radiotherapeutic Platform in New Corporate Presentation

Reuters
·
Jan 13

Cellectar Biosciences To Highlight Strategic Initiatives For 2026

Reuters
·
Jan 09

Cellectar Biosciences to highlight company’s 2026 strategic initiatives

TIPRANKS
·
Jan 09

Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference

GlobeNewswire
·
Jan 09

Director John Neis Reports Disposal of Cellectar BioSciences Inc. Common Shares

Reuters
·
Dec 17, 2025

BRIEF-Cellectar Biosciences Announces Strategic Supply Agreement With Ionetix

Reuters
·
Dec 16, 2025

Cellectar BioSciences Partners with Ionetix for Alpha-Emitting Isotope Supply

Reuters
·
Dec 16, 2025

Cellectar Biosciences Inc - Announces Multi-Year Supply Agreement With Ionetix

THOMSON REUTERS
·
Dec 16, 2025

Cellectar Biosciences Announces Strategic Supply Agreement With Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies

THOMSON REUTERS
·
Dec 16, 2025

Cellectar BioSciences Unveils Pipeline Advancements in Phospholipid Drug Conjugate Oncology Therapies

Reuters
·
Dec 06, 2025

Cellectar BioSciences reports Q3 net loss of $4.4 million

Reuters
·
Nov 13, 2025

Cellectar Biosciences Q3 net loss narrows to $4.4 mln

Reuters
·
Nov 13, 2025

Cellectar BioSciences Reports Q3 2025 Financial Results and Advances Oncology Pipeline

Reuters
·
Nov 13, 2025

Cellectar Biosciences Q3 EPS USD -1.41

THOMSON REUTERS
·
Nov 13, 2025

Cellectar Biosciences Q3 EPS $(1.41) Beats $(2.53) Estimate

Benzinga
·
Nov 13, 2025

Cellectar BioSciences Inc. to Release Third Quarter Financial Results

Reuters
·
Nov 06, 2025

Cellectar Biosciences Inc expected to post a loss of $2.53 a share - Earnings Preview

Reuters
·
Nov 06, 2025

Cellectar Says FDA Grants Rare Pediatric Drug Designation for Iopofosine in High-Grade Glioma

MT Newswires Live
·
Oct 27, 2025

Cellectar Biosciences Inc - May Receive Priority Review Voucher

THOMSON REUTERS
·
Oct 27, 2025

Cellectar Biosciences Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

THOMSON REUTERS
·
Oct 27, 2025